PERFOROMIST
LABA NEB
Formoterol fumarate · Viatris Specialty LLC
Active Medication & Mechanism
- Formoterol fumarate LABA20 mcg per 2 mL unit-dose vial
Long-acting beta2-adrenergic agonist with rapid onset of action (~5 minutes). Relaxes bronchial smooth muscle via beta2-receptor activation and increased intracellular cAMP.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
20 mcg/2 mL
1 vial (20 mcg) nebulized twice daily (morning and evening, ~12 hours apart) → 40 mcg
FDA Approved
Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema. Maximum daily dose is 40 mcg.
Not Approved
Perforomist is NOT indicated for asthma. LABA monotherapy in asthma increases risk of serious asthma-related events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
20 mcg/2 mL 1 vial (20 mcg) nebulized twice daily (morning and evening, ~12 hours apart) → 40 mcg
COPD FDA Approved
Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema. Maximum daily dose is 40 mcg.
Asthma Not Approved
Perforomist is NOT indicated for asthma. LABA monotherapy in asthma increases risk of serious asthma-related events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute deterioration of COPD. Use a SABA.
Related Inhalers
Other LABA inhalers